company background image
SAVA

Cassava Sciences NasdaqCM:SAVA Stock Report

Last Price

US$33.91

Market Cap

US$1.4b

7D

4.0%

1Y

-37.9%

Updated

28 Nov, 2022

Data

Company Financials +
SAVA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

SAVA Stock Overview

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.

Cassava Sciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cassava Sciences
Historical stock prices
Current Share PriceUS$33.91
52 Week HighUS$62.49
52 Week LowUS$13.84
Beta0.081
1 Month Change-7.75%
3 Month Change29.23%
1 Year Change-37.92%
3 Year Change1,883.04%
5 Year Change727.07%
Change since IPO-77.85%

Recent News & Updates

Recent updates

Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

Nov 19
Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

Aug 03
We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait

Apr 19
Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait

Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth

Dec 28
Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth

We Think Cassava Sciences (NASDAQ:SAVA) Can Afford To Drive Business Growth

Sep 14
We Think Cassava Sciences (NASDAQ:SAVA) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Situation

May 31
Here's Why We're Not Too Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Situation

Here's Why We're Not At All Concerned With Cassava Sciences' (NASDAQ:SAVA) Cash Burn Situation

Feb 15
Here's Why We're Not At All Concerned With Cassava Sciences' (NASDAQ:SAVA) Cash Burn Situation

How Many Cassava Sciences, Inc. (NASDAQ:SAVA) Shares Did Insiders Buy, In The Last Year?

Nov 18
How Many Cassava Sciences, Inc. (NASDAQ:SAVA) Shares Did Insiders Buy, In The Last Year?

Shareholder Returns

SAVAUS PharmaceuticalsUS Market
7D4.0%1.6%1.3%
1Y-37.9%9.9%-18.5%

Return vs Industry: SAVA underperformed the US Pharmaceuticals industry which returned 9.9% over the past year.

Return vs Market: SAVA underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is SAVA's price volatile compared to industry and market?
SAVA volatility
SAVA Average Weekly Movement17.3%
Pharmaceuticals Industry Average Movement11.0%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: SAVA is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: SAVA's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199824Remi Barbierhttps://www.cassavasciences.com

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019.

Cassava Sciences, Inc. Fundamentals Summary

How do Cassava Sciences's earnings and revenue compare to its market cap?
SAVA fundamental statistics
Market CapUS$1.41b
Earnings (TTM)-US$71.28m
Revenue (TTM)n/a

0.0x

P/S Ratio

-19.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SAVA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$25.18m
Gross Profit-US$25.18m
Other ExpensesUS$46.10m
Earnings-US$71.28m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.71
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did SAVA perform over the long term?

See historical performance and comparison